Diclofenac sodium topical solution 1.5% w/w with dimethyl sulfoxide compared with placebo for the treatment of osteoarthritis: Pooled safety results

Postgraduate Medicine

Volumn 123, Issue 6, 2011, Pages 180-188

  Roth, Sanford H ^a   Fuller, Philip ^b  

^a ARIZONA STATE UNIVERSITY   (United States)

^b MEDTRONIC INC   (United States)

Author keywords

Diclofenac; Knee; NSAID; Osteoarthritis; Solution; Topical

Indexed keywords

DICLOFENAC; DIMETHYL SULFOXIDE; PLACEBO;

ABDOMINAL DISTENSION; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ANGINA PECTORIS; ARTERIOSCLEROSIS; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; ASTHENIA; ATHEROSCLEROSIS; BULLOUS DERMATITIS; CEREBROVASCULAR ACCIDENT; COLD; CONSTIPATION; CONTACT DERMATITIS; CREATININE BLOOD LEVEL; CREATININE CLEARANCE; DIASTOLIC BLOOD PRESSURE; DIZZINESS; DRUG ERUPTION; DRUG INDUCED HEADACHE; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; DRY SKIN; DYSPEPSIA; ERYTHEMA; FLUSHING; GAMMA GLUTAMYL TRANSFERASE BLOOD LEVEL; GASTROINTESTINAL SYMPTOM; HALITOSIS; HAND DISEASE; HAND OSTEOARTHRITIS; HEART ARRHYTHMIA; HEART INFARCTION; HEART PALPITATION; HEMATOMA; HEMOGLOBIN BLOOD LEVEL; HUMAN; HYPERTENSION; KIDNEY FUNCTION; KNEE OSTEOARTHRITIS; LIMB PAIN; LOWER ABDOMINAL PAIN; MEAN ARTERIAL PRESSURE; NAUSEA; OSTEOARTHRITIS; PRURITUS; PULSE RATE; RANDOMIZED CONTROLLED TRIAL (TOPIC); SIDE EFFECT; SPIDER VEIN; SYSTOLIC BLOOD PRESSURE; THORAX PAIN; UNSPECIFIED SIDE EFFECT; UPPER ABDOMINAL PAIN; VARICOSIS; VASODILATATION; VITAL SIGN;

ADMINISTRATION, CUTANEOUS; ADULT; AGED; AGED, 80 AND OVER; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; DICLOFENAC; DIMETHYL SULFOXIDE; FEMALE; HUMANS; MALE; MIDDLE AGED; OSTEOARTHRITIS; PHARMACEUTICAL SOLUTIONS;

EID: 82155192735     PISSN: 00325481     EISSN: 19419260     Source Type: Journal    
DOI: 10.3810/pgm.2011.11.2507     Document Type: Article

References (53)

1. Centers for Disease Control and Prevention. Prevalence of doctordiagnosed arthritis and arthritis-attributable activity limitation-UnitedStates, 2007-2009. MMWR Morb Mortal Wkly Rep. 2010;59(39): 1261-1265.
2. Lawrence RC, Felson DT, Helmick CG, et al; National Arthritis Data Workgroup. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part II. Arthritis Rheum. 2008;58(1):26-35.
3. Centers for Disease Control and Prevention. Osteoarthritis. http://www.cdc.gov/arthritis/basics/osteoarthritis.htm. Updated June 25, 2010. Accessed August 1, 2011.
4. Felson DT, Zhang Y. An update on the epidemiology of knee and hip osteoarthritis with a view to prevention. Arthritis Rheum. 1998;41(8):1343-1355.
5. Rossignol M, Leclerc A, Allaert FA, et al. Primary osteoarthritis of hip, knee, and hand in relation to occupational exposure. Occup Environ Med. 2005;62(11):772-777.
6. Recommendations for the medical management of osteoarthritis of the hip and knee: 2000 update. American College of Rheumatology Subcommittee on Osteoarthritis Guidelines. Arthritis Rheum. 2000;43(9):1905-1915.
7. Jordan KM, Arden NK, Doherty M, et al; Standing Committee for International Clinical Studies Including Therapeutic Trials ESCISIT. EULAR Recommendations 2003: an evidence based approach to the management of knee osteoarthritis: report of a Task Force of the Standing Committee for International Clinical Studies Including Therapeutic Trials (ESCISIT). Ann Rheum Dis. 2003;62(12):1145-1155.
8. National Institute for Health and Clinical Excellence. Osteoarthritis: The Care and Management of Osteoarthritis in Adults. NICE clinical guideline no. 59. London, England: National Institute for Health and Clinical Excellence; 2008.
9. Zhang W, Moskowitz RW, Nuki G, et al. OARSI recommendations for the management of hip and knee osteoarthritis, Part II: OARSI evidence-based, expert consensus guidelines. Osteoarthritis Cartilage. 2008;16(2):137-162.
10. Schjerning Olsen AM, Fosbøl EL, Lindhardsen J, et al. Duration of treatment with nonsteroidal anti-inflammatory drugs and impact on risk of death and recurrent myocardial infarction in patients with prior myocardial infarction: a nationwide cohort study. Circulation. 2011;123(20):2226-2235.
11. American Geriatrics Society Panel on the Pharmacological Management of Persistent Pain in Older Persons. Pharmacological management of persistent pain in older persons. J Am Geriatr Soc. 2009;57(8): 1331-1346.
12. Zhao SZ, Burke TA, Whelton A, von Allmen H, Henderson SC. Blood pressure destabilization and related healthcare utilization among hypertensive patients using nonspecifi c NSAIDs and COX-2-specifi c inhibitors. Am J Manag Care. 2002;8(15 suppl):S401-S413.
13. Lin J, Zhang W, Jones A, Doherty M. Efficacy of topical non-steroidal anti-inflammatory drugs in the treatment of osteoarthritis: meta-analysis of randomised controlled trials. BMJ. 2004;329(7461):324.
14. PENNSAID (diclofenac sodium topical solution) 1.5% w/w [prescribing information]. Hazelwood, MO: Mallinckrodt Inc; 2010.
15. Simon LS, Grierson LM, Naseer Z, Bookman AA, Zev Shainhouse J. Efficacy and safety of topical diclofenac containing dimethyl sulfoxide (DMSO) compared with those of topical placebo, DMSO vehicle and oral diclofenac for knee osteoarthritis. Pain. 2009;143(3):238-245.
16. Tugwell PS, Wells GA, Shainhouse JZ. Equivalence study of a topical diclofenac solution (PENNSAID®) compared with oral diclofenac in symptomatic treatment of osteoarthritis of the knee: a randomized controlled trial. J Rheumatol. 2004;31(10):2002-2012.
17. Roth SH, Fuller P. Diclofenac topical solution compared with oral diclofenac: a pooled safety analysis. J Pain Res. 2011;4:159-167.
18. Roth SH, Shainhouse JZ. Effi cacy and safety of a topical diclofenac solution (pennsaid) in the treatment of primary osteoarthritis of the knee: a randomized, double-blind, vehicle-controlled clinical trial. Arch Intern Med. 2004;164(18):2017-2023.
19. A double-blinded, placebo controlled, four-way parallel, clinical trial to evaluate the safety and efficacy of PENNSAID treatment of the osteoarthritic hand. Phase III Trial Clinical Study Report. Dimethaid Health Care, Inc. Report date May 2000.
20. A double-blind, placebo controlled, three-way, parallel study of the safety and effi cacy of Dimethaid-D (PENNSAID) topical lotion in the treatment of osteoarthritis. Phase III Trial Clinical Study Report. Dimethaid Health Care, Inc. Report date October 2000.
21. Bookman AA, Williams KS, Shainhouse JZ. Effect of topical diclofenac solution for relieving symptoms of primary osteoarthritis of the knee: a randomized controlled trial. CMAJ. 2004;171(4):333-338.
22. Baer PA, Thomas LM, Shainhouse Z. Treatment of osteoarthritis of the knee with a topical diclofenac solution: a randomised controlled, 6-week trial [ISRC TN53366886]. BMC Musculoskelet Disord. 2005;6:44.
23. Roth SH. Nonsteroidal anti-inflammatory drugs: gastropathy, deaths, and medical practice. Ann Intern Med. 1988;109(5):353-354.
24. Roth SH, Bennett RE. Nonsteroidal anti-inflammatory drug gastropathy. Recognition and response. Arch Intern Med. 1987;147(12): 2093-2100.
25. Roth SH. Nonsteroidal antiinflammatory drug gastropathy: we started it, why don't we stop it? J Rheumatol. 2005;32(7):1189-1191.
26. Bombardier C, Laine L, Reicin A, et al; VIGOR Study Group. Comparison of upper gastrointestinal toxicity of rofecoxib and naproxen in patients with rheumatoid arthritis. N Engl J Med. 2000;343(21): 1520-1528.
27. Bresalier RS, Sandler RS, Quan H, et al; Adenomatous Polyp Prevention on Vioxx (APPROVe) Trial Investigators. Cardiovascular events associated with rofecoxib in a colorectal adenoma chemoprevention trial. N Engl J Med. 2005;352(11):1092-1102.
28. Lévesque LE, Brophy JM, Zhang B. The risk for myocardial infarction with cyclooxygenase-2 inhibitors: a population study of elderly adults. Ann Intern Med. 2005;142(7):481-489.
29. Solomon SD, McMurray JJ, Pfeffer MA, et al; Adenoma Prevention with Celecoxib (APC) Study Investigators. Cardiovascular risk associated with celecoxib in a clinical trial for colorectal adenoma prevention. N Engl J Med. 2005;352(11):1071-1080.
30. Becker MC, Thomas TH, Wisniewski L, et al; PRECISION Investigators. Rationale, design, and governance of Prospective Randomized Evaluation of Celecoxib Integrated Safety versus Ibuprofen Or Naproxen (PRECISION), a cardiovascular end point trial of nonsteroidal antiinflammatory agents in patients with arthritis. Am Heart J. 2009;157(4):606-612.
31. Turajane T, Wongbunnak R, Patcharatrakul T, Ratansumawong K, Poigampetch Y, Songpatanasilp T. Gastrointestinal and cardiovascular risk of non-selective NSAIDs and COX-2 inhibitors in elderly patients with knee osteoarthritis. J Med Assoc Thai. 2009;92(suppl 6): S19-S26.
32. Hinz B, Dormann H, Brune K. More pronounced inhibition of cyclooxygenase 2, increase in blood pressure, and reduction of heart rate by treatment with diclofenac compared with celecoxib and rofecoxib. Arthritis Rheum. 2006;54(1):282-291.
33. Hui X, Hewitt PG, Poblete N, Maibach HI, Shainhouse JZ, Wester RC. In vivo bioavailability and metabolism of topical diclofenac lotion in human volunteers. Pharm Res. 1998;15(10):1589-1595.
34. Keinzler JL, Gold M, Nollevaux F. Systemic bioavailability of topical diclofenac sodium gel 1% versus oral diclofenac sodium in healthy volunteers. J Clin Pharmacol. 2010;50(1):50-61.
35. Chan FK. Primer: managing NSAID-induced ulcer complications-balancing gastrointestinal and cardiovascular risks. Nat Clin Pract Gastroenterol Hepatol. 2006;3(10):563-567.
36. Ofman JJ, MacLean CH, Straus WL, et al. A metaanalysis of severe upper gastrointestinal complications of nonsteroidal antiinflammatory drugs. J Rheumatol. 2002;29(4):804-812.
37. Boers M, Tangelder MJ, van Ingen H, et al. The rate of NSAIDinduced endoscopic ulcers increases linearly but not exponentially with age: a pooled analysis of 12 randomised trials. Ann Rheum Dis. 2007;66(3):417-418.
38. Bardou M, Barkun AN. Preventing the gastrointestinal adverse effects of nonsteroidal anti-inflammatory drugs: from risk factor identifi cation to risk factor intervention. Joint Bone Spine. 2010;77(1):6-12.
39. Barthel HR, Axford-Gatley RA. Topical nonsteroidal anti-inflammatory drugs for osteoarthritis. Postgrad Med. 2010;122(6):98-106.
40. Rahme E, Barkun AN, Toubouti Y, et al. Do proton-pump inhibitors confer additional gastrointestinal protection in patients given celecoxib? Arthritis Rheum. 2007;57(5):748-755.
41. Eom CS, Park SM, Myung SK, et al. Use of acid-suppressive drugs and risk of fracture: a meta-analysis of observational studies. Ann Fam Med. 2011;9(3):257-267.
42. Cundy T, Dissanayake A. Severe hypomagnesaemia in long-term users of proton-pump inhibitors. Clin Endocrinol (Oxf). 2008;69(2):338-341.
43. Juhász M, Herszényi L, Tulassay Z. Current standings of the proton pump inhibitor and clopidogrel co-therapy: review on an evolving field with the eyes of the gastroenterologist. Digestion. 2010;81(1):10-15.
44. Makris UE, Kohler MJ, Fraenkel L. Adverse effects of topical nonsteroidal antiinflammatory drugs in older adults with osteoarthritis: a systematic literature review. J Rheumatol. 2010;37(6):1236-1243.
45. Scott PA, Kingsley GH, Smith CM, Choy EH, Scott DL. Non-steroidal anti-inflammatory drugs and myocardial infarctions: comparative systematic review of evidence from observational studies and randomised controlled trials. Ann Rheum Dis. 2007;66(10):1296-1304.
46. Kearney PM, Baigent C, Godwin J, Halls H, Emberson JR, Patrono C. Do selective cyclo-oxygenase-2 inhibitors and traditional non-steroidal anti-inflammatory drugs increase the risk of atherothrombosis? Metaanalysis of randomised trials. BMJ. 2006;332(7553):1302-1308.
47. Johnson AG, Nguyen TV, Day RO. Do nonsteroidal anti-inflammatory drugs affect blood pressure? A meta-analysis. Ann Intern Med. 1994;121(4):289-300.
48. Brater DC, Anderson S, Baird B, et al. Effects of ibuprofen, naproxen, and sulindac on prostaglandins in men. Kidney Int. 1985;27(1):66-73.
49. O'Connor N, Dargan PI, Jones AL. Hepatocellular damage from nonsteroidal anti-inflammatory drugs. QJM. 2003;96(11):787-791.
50. Aithal GP, Day CP. Nonsteroidal anti-inflammatory drug-induced hepatotoxicity. Clin Liver Dis. 2007;11(3):563-575.
51. Banks AT, Zimmerman HJ, Ishak KG, Harter JG. Diclofenacassociated hepatotoxicity: analysis of 180 cases reported to the Food and Drug Administration as adverse reactions. Hepatology. 1995; 22(3):820-827.
52. Barthel HR, Haselwood D, Longley S 3rd, et al. Randomized controlled trial of diclofenac sodium gel in knee osteoarthritis. Semin Arthritis Rheum. 2009;39(3):203-212.
53. Shainhouse JZ, Grierson LM, Naseer Z. A long-term, open-label study to confi rm the safety of topical diclofenac solution containing dimethyl sulfoxide in the treatment of the osteoarthritic knee. Am J Ther. 2010;17(6):566-576.